Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amneal Taps Strides To Add More Competition To US Vascepa Market

Originator Amarin Claims Continued Market Lead – Three Years After First Generic Launch

Executive Summary

Amneal has in-licensed Strides’ generic version of Vascepa to compete with the several ANDA products already on the market.

You may also be interested in...

Amneal Insists Generics Are Sustainable As It Eyes Further Growth Avenues

Amneal trumpeted its continued faith in the retail generics market at the recent J.P. Morgan Healthcare Conference, as the US-based player also discussed longer-term goals for its burgeoning injectables and biosimilars portfolios.

Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon

Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.

Amneal Generics Unit Continues To Grow Following Complex Products Shift

Amneal’s generics portfolio delivered considerable growth during Q3, as a result of its ongoing shift toward complex products and successful new launches.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts